TScan Therapeutics, Inc.

TCRX Nasdaq CIK: 0001783328

Company Information

Industry Biological Products, (No Diagnostic Substances)
SIC Code 2836
Entity Type operating
SEC Category Emerging growth company
State of Incorporation DE
Business Address 830 WINTER STREET, WALTHAM, MA, 02451
Mailing Address 830 WINTER STREET, WALTHAM, MA, 02451
Phone 857-399-9500
Fiscal Year End 1231
EIN 825282075

Financial Overview

FY2025

$-1.00
EPS

Recent SEC Filings

Form Type Date Filed Document
8-K Current report of material events April 2, 2026 View on SEC
10-K Annual financial report March 4, 2026 View on SEC
8-K Current report of material events March 4, 2026 View on SEC
4 Insider stock transaction report January 22, 2026 View on SEC
4 Insider stock transaction report January 22, 2026 View on SEC
4 Insider stock transaction report January 22, 2026 View on SEC
4 Insider stock transaction report January 22, 2026 View on SEC
4 Insider stock transaction report January 22, 2026 View on SEC
8-K Current report of material events January 12, 2026 View on SEC
4 Insider stock transaction report December 23, 2025 View on SEC

Annual Reports

10-K March 4, 2026
  • Strong collaboration revenue growth of over 260% to $10.3 million in 2025, primarily driven by the Amgen partnership.
  • Lead blood cancer programs, TSC-100 and TSC-101, are advancing through Phase 1 clinical trials with strategic prioritization in late 2025.
View Analysis

Insider Trading

BUY 1 insiders 3 recent transactions
View Full Insider Trading Profile

Related Companies

Companies in the same industry (SIC: 2836)

Investor Resources

Learn more about SEC filings and how to research public companies.

Important Disclaimer

This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.